Oruka Therapeutics' (ORKA) Outperform Rating Reiterated at Wedbush

Key Points

• Wedbush reaffirmed its “Outperform” rating on Oruka Therapeutics and set a $165 price target, implying 59.34% potential upside from the prior close. Analysts broadly remain positive, with a consensus “Moderate Buy” rating and $134.30 average target.
• Oruka shares traded at $103.55, near their 52-week high of $107.55, while the company reported a quarterly loss of $0.55 per share—$0.04 worse than analyst expectations.
• Insiders sold $12.0 million of stock over the past 90 days under pre-arranged trading plans, while institutional investors own 56.44% of the company. Oruka is developing peptide-based cancer therapies, with lead candidate ONCT-01 in Phase 1 trials.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report)'s stock had its "outperform" rating reaffirmed by equities researchers at Wedbush in a note issued to investors on Tuesday,Benzinga reports. They currently have a $165.00 target price on the stock. Wedbush's price objective points to a potential upside of 59.34% from the company's previous close.

A number of other research analysts also recently commented on ORKA. HC Wainwright restated a "buy" rating and set a $120.00 price objective on shares of Oruka Therapeutics in a research note on Monday, August 3rd. Barclays boosted their price target on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an "overweight" rating in a report on Monday, April 27th. Guggenheim set a $200.00 price target on shares of Oruka Therapeutics and gave the stock a "buy" rating in a research report on Monday, April 27th. Leerink Partners set a $120.00 price objective on shares of Oruka Therapeutics in a report on Thursday, April 30th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $180.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $134.30.

Oruka Therapeutics Stock Performance

Shares of NASDAQ ORKA traded down $1.59 during midday trading on Tuesday, hitting $103.55. The company's stock had a trading volume of 35,156 shares, compared to its average volume of 1,138,015. Oruka Therapeutics has a 1-year low of $13.06 and a 1-year high of $107.55. The firm's fifty day moving average price is $83.59 and its 200-day moving average price is $60.75. The firm has a market cap of $6.25 billion, a P/E ratio of -53.67 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). As a group, research analysts predict that Oruka Therapeutics will post -2.06 earnings per share for the current fiscal year.

Insider Activity at Oruka Therapeutics

In related news, Director Carl Dambkowski sold 105,000 shares of the business's stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $58.97, for a total transaction of $6,191,850.00. Following the sale, the director owned 73,743 shares of the company's stock, valued at $4,348,624.71. The trade was a 58.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,290 shares of the company's stock in a transaction on Monday, May 18th. The shares were sold at an average price of $59.07, for a total value of $607,830.30. Following the completion of the sale, the senior vice president owned 16,406 shares of the company's stock, valued at approximately $969,102.42. This trade represents a 38.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 188,406 shares of company stock worth $12,019,683 over the last ninety days. Insiders own 23.49% of the company's stock.

Hedge Funds Weigh In On Oruka Therapeutics

Several large investors have recently made changes to their positions in ORKA. Moody Aldrich Partners LLC acquired a new position in shares of Oruka Therapeutics in the fourth quarter worth about $3,844,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Oruka Therapeutics in the first quarter valued at $1,811,000. SG Americas Securities LLC acquired a new stake in shares of Oruka Therapeutics in the fourth quarter worth $251,000. Perceptive Advisors LLC boosted its position in shares of Oruka Therapeutics by 16.4% in the fourth quarter. Perceptive Advisors LLC now owns 1,476,501 shares of the company's stock worth $44,753,000 after buying an additional 208,480 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Oruka Therapeutics by 18.3% during the first quarter. The Manufacturers Life Insurance Company now owns 72,563 shares of the company's stock valued at $3,559,000 after buying an additional 11,205 shares in the last quarter. Institutional investors own 56.44% of the company's stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source